FDCP
EW icon

Foster Dykema Cabot & Partners’s Edwards Lifesciences EW Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-146
Closed -$9.63K – 413
2024
Q3 		$9.63K Sell
146
-56
-28% -$4.07K ﹤0.01% 370
2024
Q2 		$18.7K Buy
202
+46
+29% +$4.07K ﹤0.01% 229
2024
Q1 		$14.9K Buy
156
+146
+1,460% +$12.3K ﹤0.01% 257
2023
Q4 		$763 Buy
+10
New +$696 ﹤0.01% 264

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Foster Dykema Cabot & Partners's EW Position: Q4 2024 in Review

Foster Dykema Cabot & Partners sold out of Edwards Lifesciences (EW) in Q4 2024, closing a stake of 146 shares — an estimated $9.63K sold.

Foster Dykema Cabot & Partners first reported a position in EW in Q4 2023 and held it in 4 quarters. The position peaked at $18.7K in Q2 2024. 1,229 funds tracked by Wall St. Rank hold EW as of Q4 2024.

  • Foster Dykema Cabot & Partners reported no remaining Edwards Lifesciences position as of Q4 2024 after selling out during the quarter.
  • Foster Dykema Cabot & Partners sold 146 Edwards Lifesciences shares in Q4 2024, an estimated $9.63K.
  • Foster Dykema Cabot & Partners first reported a position in Edwards Lifesciences in Q4 2023 and held it in 4 quarters.
  • Foster Dykema Cabot & Partners's Edwards Lifesciences position peaked at $18.7K in Q2 2024.
  • 1,229 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2024.

Based on Foster Dykema Cabot & Partners's 13F filing for Q4 2024, filed 13 Feb 2025.